{"id":30175,"date":"2025-03-24T17:42:55","date_gmt":"2025-03-24T09:42:55","guid":{"rendered":"https:\/\/flcube.com\/?p=30175"},"modified":"2025-03-24T17:42:56","modified_gmt":"2025-03-24T09:42:56","slug":"syneron-bio-collaborates-with-astrazeneca-to-develop-macrocyclic-peptides-for-chronic-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=30175","title":{"rendered":"Syneron Bio Collaborates with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases"},"content":{"rendered":"\n

China-based Syneron Bio, a biotech firm specializing in macrocyclic peptide drugs, has entered into a partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN<\/a>). The collaboration centers on developing potential first-in-class macrocyclic peptides targeting chronic diseases, with AstraZeneca gaining access to Syneron Bio’s innovative Synova platform.<\/p>\n\n\n\n

Synova Platform and Research Focus<\/strong>
The Synova platform is an intelligent and high-throughput macrocyclic peptide drug research and development platform. It is designed to support research programs exploring future treatments for chronic diseases, including rare, autoimmune, and metabolic conditions. This platform represents a significant advancement in the discovery and optimization of macrocyclic peptide therapeutics.<\/p>\n\n\n\n

Financial Terms and Milestones<\/strong>
Under the deal terms, AstraZeneca will provide upfront payments and potential near-term milestone payments totaling USD 75 million. The agreement also includes up to USD 3.4 billion in additional development and commercial milestones, along with tiered royalties based on global sales. This substantial financial commitment reflects the potential of the collaboration to yield novel treatments for unmet medical needs.<\/p>\n\n\n\n

Expansion of R&D Capabilities<\/strong>
Furthermore, AstraZeneca will make an equity investment in Syneron Bio, which expects to expand its Beijing R&D center through this collaboration. This expansion will enhance Syneron Bio’s research capabilities and accelerate the development of innovative therapies for chronic diseases.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Syneron Bio, a biotech firm specializing in macrocyclic peptide drugs, has entered into a…<\/p>\n","protected":false},"author":1,"featured_media":30176,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[130,30,871,3877],"class_list":["post-30175","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-astrazeneca","tag-biotech","tag-nasdaq-azn","tag-syneron-bio"],"yoast_head":"\nSyneron Bio Collaborates with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Syneron Bio, a biotech firm specializing in macrocyclic peptide drugs, has entered into a partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN). The collaboration centers on developing potential first-in-class macrocyclic peptides targeting chronic diseases, with AstraZeneca gaining access to Syneron Bio's innovative Synova platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=30175\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Syneron Bio Collaborates with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases\" \/>\n<meta property=\"og:description\" content=\"China-based Syneron Bio, a biotech firm specializing in macrocyclic peptide drugs, has entered into a partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN). The collaboration centers on developing potential first-in-class macrocyclic peptides targeting chronic diseases, with AstraZeneca gaining access to Syneron Bio's innovative Synova platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=30175\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-24T09:42:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-24T09:42:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2407-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30175#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30175\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Syneron Bio Collaborates with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases\",\"datePublished\":\"2025-03-24T09:42:55+00:00\",\"dateModified\":\"2025-03-24T09:42:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30175\"},\"wordCount\":225,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30175#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2407-png.webp\",\"keywords\":[\"AstraZeneca\",\"Biotech\",\"NASDAQ: AZN\",\"Syneron Bio\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30175#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30175\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=30175\",\"name\":\"Syneron Bio Collaborates with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30175#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30175#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2407-png.webp\",\"datePublished\":\"2025-03-24T09:42:55+00:00\",\"dateModified\":\"2025-03-24T09:42:56+00:00\",\"description\":\"China-based Syneron Bio, a biotech firm specializing in macrocyclic peptide drugs, has entered into a partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN). The collaboration centers on developing potential first-in-class macrocyclic peptides targeting chronic diseases, with AstraZeneca gaining access to Syneron Bio's innovative Synova platform.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30175#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=30175\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30175#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2407-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/2407-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Syneron Bio Collaborates with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=30175#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Syneron Bio Collaborates with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Syneron Bio Collaborates with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases - Insight, China's Pharmaceutical Industry","description":"China-based Syneron Bio, a biotech firm specializing in macrocyclic peptide drugs, has entered into a partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN). The collaboration centers on developing potential first-in-class macrocyclic peptides targeting chronic diseases, with AstraZeneca gaining access to Syneron Bio's innovative Synova platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=30175","og_locale":"en_US","og_type":"article","og_title":"Syneron Bio Collaborates with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases","og_description":"China-based Syneron Bio, a biotech firm specializing in macrocyclic peptide drugs, has entered into a partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN). The collaboration centers on developing potential first-in-class macrocyclic peptides targeting chronic diseases, with AstraZeneca gaining access to Syneron Bio's innovative Synova platform.","og_url":"https:\/\/flcube.com\/?p=30175","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-24T09:42:55+00:00","article_modified_time":"2025-03-24T09:42:56+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2407-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=30175#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=30175"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Syneron Bio Collaborates with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases","datePublished":"2025-03-24T09:42:55+00:00","dateModified":"2025-03-24T09:42:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=30175"},"wordCount":225,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=30175#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2407-png.webp","keywords":["AstraZeneca","Biotech","NASDAQ: AZN","Syneron Bio"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=30175#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=30175","url":"https:\/\/flcube.com\/?p=30175","name":"Syneron Bio Collaborates with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=30175#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=30175#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2407-png.webp","datePublished":"2025-03-24T09:42:55+00:00","dateModified":"2025-03-24T09:42:56+00:00","description":"China-based Syneron Bio, a biotech firm specializing in macrocyclic peptide drugs, has entered into a partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN). The collaboration centers on developing potential first-in-class macrocyclic peptides targeting chronic diseases, with AstraZeneca gaining access to Syneron Bio's innovative Synova platform.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=30175#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=30175"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=30175#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2407-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2407-png.webp","width":1080,"height":608,"caption":"Syneron Bio Collaborates with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=30175#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Syneron Bio Collaborates with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/03\/2407-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30175","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30175"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30175\/revisions"}],"predecessor-version":[{"id":30177,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/30175\/revisions\/30177"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/30176"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30175"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}